Maguire et al. reported the long-term treatment outcomes of anti-VEGF agents, including bevacizumab and ranibizumab, for treating nAMD in an extended comparison of AMD treatments trial study [16]. The gene discussed is VEGFA; the disease is age-related macular degeneration.